These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17703638)

  • 1. Rimonabant for treating tobacco dependence.
    Steinberg MB; Foulds J
    Vasc Health Risk Manag; 2007; 3(3):307-11. PubMed ID: 17703638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    Cahill K; Ussher M
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005353. PubMed ID: 17943852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 7. The endogenous cannabinoid system modulates nicotine reward and dependence.
    Merritt LL; Martin BR; Walters C; Lichtman AH; Damaj MI
    J Pharmacol Exp Ther; 2008 Aug; 326(2):483-92. PubMed ID: 18451315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on therapeutics for tobacco dependence.
    Lancaster T; Stead L; Cahill K
    Expert Opin Pharmacother; 2008 Jan; 9(1):15-22. PubMed ID: 18076335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].
    Kvasnicka T
    Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.
    Buchhalter AR; Fant RV; Henningfield JE
    Drugs; 2008; 68(8):1067-88. PubMed ID: 18484799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
    Tucci SA; Halford JC; Harrold JA; Kirkham TC
    Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecule of the month. Rimonabant hydrochloride.
    Drug News Perspect; 2004; 17(6):403. PubMed ID: 15334190
    [No Abstract]   [Full Text] [Related]  

  • 17. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).
    Cohen C; Perrault G; Griebel G; Soubrié P
    Neuropsychopharmacology; 2005 Jan; 30(1):145-55. PubMed ID: 15292905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking cessation: lessons learned from clinical trial evidence.
    Reid RD; Quinlan B; Riley DL; Pipe AL
    Curr Opin Cardiol; 2007 Jul; 22(4):280-5. PubMed ID: 17556878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.